Filing Analysis
OS Therapies Inc. entered into an Open Market Sale Agreement with Jefferies LLC to facilitate an 'at the market' (ATM) offering of common stock. The company intends to sell up to $75 million in shares to fund clinical development and R&D activities.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of up to $75 million in new common stock.
- ATM offerings are often used by micro-cap companies to manage immediate liquidity needs, which can create downward pressure on the stock price during selling periods.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026.
- The ATM offering has an aggregate maximum price of up to $75 million.
- The offering is conducted under a previously effective S-3 shelf registration statement (File No. 333-289443).
- Jefferies LLC will receive a 3.0% commission on aggregate gross proceeds.
- The company will reimburse Jefferies LLC for legal fees/disbursements up to $100,000.
- Proceeds are earmarked for clinical development, R&D, and potential strategic acquisitions/investments.
OS Therapies Inc. entered into a securities purchase agreement for a two-tranche private placement of senior secured convertible promissory notes totaling up to $10,000,000. The first tranche of $5,000,000 has already closed, involving the conversion of an existing bridge note and the issuance of new debt with significant equity warrants.
🚩 Red Flags
- Highly dilutive structure: The issuance includes significant warrants and pre-funded warrants for the purchasers.
- Short maturity: 9-month maturity on senior secured debt indicates a high-pressure liquidity need.
- Expensive capital: 9% interest plus an Original Issue Discount (OID) of 7.5%.
- Minimum interest penalty: Prepayment within the first year triggers a full year's worth of interest, increasing the cost of capital.
📋 Key Facts
- Total offering amount: Up to $10,000,000 in senior secured convertible promissory notes.
- First Tranche ($5,000,000) closed on August 10, 2026, including the conversion of a $2.2M bridge note from August 2, 2026.
- Notes carry a 9.0% annual interest rate, payable monthly in arrears.
- Conversion price set at $2.05 per share (subject to adjustments).
- Each unit includes a Note, 30,000 shares/pre-funded warrants, and five-year warrants for 30,000 shares.
- Notes have a maturity term of nine months from the advance date.
- Includes a 'minimum interest' clause requiring one full year of interest even if prepaid within 12 months.
- The company is prohibited from entering into variable rate transactions (e.g., equity lines) while notes are outstanding.
OS Therapies entered into a settlement agreement with Leonite Fund I to resolve outstanding obligations under a $10M senior secured convertible note. To fund the $1.9M cash settlement and 500,000 share issuance, the company issued a new $2.2M bridge convertible promissory note to an accredited investor.
🚩 Red Flags
- High-interest/Short-term debt: The company is using a new $2.2M bridge note maturing in less than one month to pay off previous debt, indicating immediate liquidity pressure.
- Dilutive settlement: Settling debt via the issuance of 500,000 shares plus existing warrants suggests significant potential dilution for current shareholders.
- Security interest: The original Leonite Note was secured by substantially all company assets (excluding IP).
- Rapid refinancing cycle: Moving from a $1.6M funded tranche to a new $2.2M bridge note within days indicates extreme volatility in capital structure.
📋 Key Facts
- Settlement Agreement dated July 31, 2026, with Leonite Fund I, LP to satisfy all amounts under the Leonite Note.
- Settlement terms: $1,900,000 cash payment and issuance of 500,000 shares of common stock by August 7, 2026.
- The settlement will terminate a prior warrant to purchase up to 1,750,000 shares at $2.85/share.
- Issued a new $2,200,000 Bridge Convertible Promissory Note on August 2, 2026, maturing September 1, 2026 (unless converted).
- The Bridge Note proceeds were used to fund the Leonite Settlement Payment.
OS Therapies Inc. has terminated its At-Market Issuance Sales Agreement with B. Riley Securities, Inc. and JonesTrading Institutional Services LLC. The termination is effective July 28, 2026, effectively ending the company's ability to raise up to $17.47 million through this specific equity program.
🚩 Red Flags
- Loss of a significant capital raising mechanism ($17.5M remaining) which may indicate difficulty in accessing equity markets or a shift in financing strategy.
- The company has only utilized ~3% of the total available offering capacity, suggesting either a lack of need for immediate cash (unlikely for micro-cap biotech) or an inability to execute sales effectively.
📋 Key Facts
- Termination of At-Market Issuance Sales Agreement dated August 8, 2025.
- Effective date of termination: July 28, 2026.
- Total aggregate offering amount under the agreement was $18,000,000.
- Amount already raised through this agreement: approximately $530,162 (via 282,679 shares).
- Remaining capacity under the agreement at time of termination: approximately $17,469,838.
- No termination fees or payments are due to either party.
This is an amendment (8-K/A) to a previous filing, submitted to include a previously omitted side letter related to a private placement transaction with Leonite Fund I, LP. The underlying transaction involves senior secured convertible promissory notes and common stock purchase warrants.
🚩 Red Flags
- Use of convertible promissory notes and warrants often indicates dilutive financing for micro-cap companies.
- The inclusion of a 'Side Letter' in an amendment can sometimes indicate terms that were not initially disclosed, though here it is characterized as an inadvertent omission.
📋 Key Facts
- Amendment filed on July 7, 2026, to include Exhibit 10.3 (Side Letter) omitted from the July 2, 2026 filing.
- The side letter is dated June 30, 2026, and involves Leonite Fund I, LP.
- The transaction includes a Securities Purchase Agreement and a Pledge and Security Agreement.
- Financing instruments include Senior Secured Convertible Promissory Notes and Common Stock Purchase Warrants.
OS Therapies Inc. entered into a $10 million senior secured convertible promissory note agreement with Leonite Fund I, LP to fund clinical development and working capital. The deal includes significant equity warrants and anti-dilution protections that pose substantial dilution risk to existing shareholders.
🚩 Red Flags
- Significant dilution risk via convertible note, commitment shares, and warrants.
- Anti-dilution/Price-reset feature: Conversion price adjusts if the company issues securities at a lower effective price.
- Draconian default terms: 125% principal penalty and 24% interest rate upon event of default.
- Restrictive covenants: Limitations on issuing variable rate transactions or equity line of credit arrangements.
- Investor has right of first refusal and participation rights in future offerings.
📋 Key Facts
- Total principal amount of the Note: up to $10,000,000.
- First tranche of $1,600,000 (less $35,000 in legal fees) expected July 2, 2026.
- Interest rate is 9.0% per annum, payable monthly.
- Conversion price: initial $2.05 per share, subject to customary adjustments and a floating/price-reset feature.
- Investor receives 275,000 commitment shares and a warrant to purchase up to 1,750,000 shares.
- Note maturity is 9 months after each tranche advance (max 24 months from issue).
- Includes 'most-favored-nation' rights and participation rights for the investor.
OS Therapies announced that the European Medicines Agency (EMA) has initiated a rolling review of the regulatory dossier for its lead candidate, OST-HER2. The company also presented immune pharmacodynamic biomarker response data and provided updates on regulatory interactions during a conference call.
📋 Key Facts
- The EMA initiated a rolling review (continuous evaluation) of the OST-HER2 regulatory dossier on April 30, 2026.
- The company held a conference call to review OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data.
- The filing includes a press release (Exhibit 99.1) and a slide presentation (Exhibit 99.2) detailing the regulatory and clinical updates.
- OS Therapies is an emerging growth company based in Grasonville, Maryland.
OS Therapies Inc. entered into a securities purchase agreement for a registered direct offering of common stock and warrants, raising approximately $4.7 million in net proceeds. The offering includes 2,505,073 shares of common stock (or pre-funded warrants) and 3,755,966 accompanying common warrants.
🚩 Red Flags
- Significant potential dilution from 100% warrant coverage (3.75 million common warrants vs 3.75 million shares/pre-funded warrants sold).
- The inclusion of a 'Variable Rate Transaction' prohibition for 180 days often indicates a history of or vulnerability to dilutive 'death spiral' financing.
📋 Key Facts
- The offering price was $1.40 per share and accompanying common warrant.
- Total net proceeds are approximately $4.7 million after fees and expenses.
- Common warrants have an exercise price of $1.40 and a five-year term.
- The company is subject to a 90-day lock-up on new share issuances and a 180-day ban on variable rate transactions.
- Placement agent Ceros Financial Services received a 7% cash fee and warrants to purchase 187,798 shares at $1.54.
- Proceeds are earmarked for clinical development, R&D, and potential acquisitions.
OS Therapies Inc. filed a prospectus supplement for the resale of up to 10,529,417 shares of common stock by selling stockholders. The filing provides the necessary legal opinion for shares registered under an existing Form S-3 shelf registration statement.
🚩 Red Flags
- Significant share overhang: The registration of 10,529,417 shares for resale may create substantial downward price pressure as selling stockholders exit their positions.
📋 Key Facts
- Resale of up to 10,529,417 shares of common stock by selling stockholders.
- The shares are registered under Form S-3 (File No. 333-289443), which became effective on August 12, 2025.
- The filing includes a legal opinion from Olshan Frome Wolosky LLP regarding the legality of the shares.
- The company will not receive proceeds from the sale of these shares by the selling stockholders.
OS Therapies entered into a securities purchase agreement for a private placement of $2.2 million in 10% original issue discount (OID) convertible promissory notes and 1.67 million warrants. The financing provides $2 million in gross proceeds to fund clinical development and R&D, but carries highly dilutive terms including a 10% discount to market price for voluntary conversions.
🚩 Red Flags
- High-cost capital with a 10% Original Issue Discount (OID).
- Variable rate conversion feature (90% of VWAP) creates potential for 'death spiral' dilution if stock price declines.
- Full-ratchet anti-dilution provisions protect investors at the expense of existing shareholders.
- Restrictive negative covenants limit the company's ability to incur additional debt or pay dividends.
📋 Key Facts
- Issued $2,200,000 in principal amount of 10% OID unsecured convertible promissory notes for $2,000,000 in gross proceeds.
- Notes bear 4% annual interest and mature on March 4, 2027.
- Voluntary conversion price set at 90% of the 10-day volume weighted average price (VWAP).
- Issued 1,666,667 warrants with an exercise price of $1.40 and a five-year term.
- Includes full-ratchet anti-dilution protection for both notes and warrants.
- Mandatory conversion occurs if the company completes a 'Qualified Offering' of at least $2,500,000.
- Placement agent received a 7% cash fee plus $25,000 in expense reimbursements.
OS Therapies Inc. has extended the offering period for its warrant solicitation, which allows existing warrant holders to exercise warrants at a reduced price of $1.40 per share in exchange for new warrants.
🚩 Red Flags
- Significant potential dilution: The issuance of new warrants for up to 5.38 million shares represents a substantial increase in the share count.
- Distressed financing mechanism: Reducing exercise prices to induce cash is often a sign of liquidity pressure or difficulty raising capital through traditional means.
- Concentrated participation: The transaction involves fewer than 10 accredited investors, indicating highly specialized/private terms.
📋 Key Facts
- The company entered into inducement offer letter agreements on January 10, 2026.
- Less than 10 accredited investors are participating in the warrant exercise/pre-funding.
- Existing Warrants cover up to 5,382,148 shares of common stock.
- Exercise price for existing warrants is reduced to $1.40 per share (or $1.399 for pre-funded shares).
- In exchange, the company will issue new warrants to purchase up to 5,382,148 shares at an exercise price of $1.40 per share.
- The offering period was extended from February 10, 2026, to March 2, 2026.
OS Therapies Inc. has entered into inducement agreements with less than 10 accredited investors to encourage the exercise of existing warrants at a reduced price of $1.40 per share in exchange for issuing new warrants. The company expects to raise approximately $7.5 million in gross proceeds to fund regulatory efforts and a potential spinoff.
🚩 Red Flags
- Warrant Inducement: Using reduced exercise prices to induce warrant holders to provide immediate cash is often a sign of urgent liquidity needs.
- Potential Dilution: The issuance of over 5.3 million new warrants represents significant potential dilution for existing shareholders.
- Pre-funding mechanism: Provisions allowing holders to pre-fund at $0.001 per share effectively bypasses ownership limits and creates highly dilutive equity structures.
📋 Key Facts
- Inducement period: January 10, 2026, to February 10, 2026.
- Exercise price for existing warrants: $1.40 per share.
- New warrants issued: Up to 5,382,148 shares at an exercise price of $1.40 per share with a 5-year term.
- Expected gross proceeds: Approximately $7.5 million (before fees).
- Solicitation Agent fee: 8.0% of total gross cash proceeds plus up to $25,000 in expenses.
- Use of proceeds: OST-HER2 regulatory/pre-commercial efforts, OS Animal Health spinoff preparations, and general corporate purposes.
OS Therapies Inc. reported the results of its 2025 annual meeting of stockholders, where shareholders approved several critical structural and compensatory measures, including a massive increase in authorized share count and an issuance to Ayala Pharmaceuticals.
🚩 Red Flags
- Significant dilution risk: The charter amendment triples authorized shares (from 50M to 150M) and the Ayala issuance could represent >20% of the company.
- Incentive Plan expansion: Increasing available shares for compensation from 4M to 10M suggests potential further dilution via equity-based compensation.
📋 Key Facts
- Stockholders approved increasing authorized common stock from 50 million to 150 million shares (Charter Amendment).
- Approved the 'Ayala Issuance' of common stock or warrants to Ayala Pharmaceuticals, Inc., potentially exceeding 20% of outstanding shares.
- Approved an amendment to the 2023 Incentive Compensation Plan, increasing available shares from 4 million to 10 million.
- Adopted a resolution authorizing the board to implement a shareholder rights agreement (often associated with anti-takeover measures).
- Ratified MaloneBailey, LLP as independent auditor for fiscal year 2025.
OS Therapies Inc. announced the adjournment of its 2025 annual meeting to October 21, 2025, to allow for additional proxy solicitation. Preliminary results indicate that all three proposals—the Issuance Proposal, Charter Amendment Proposal, and Auditor Ratification Proposal—have received the requisite votes.
🚩 Red Flags
- Adjournment of annual meeting to solicit more votes may indicate uncertainty in reaching the required quorum or specific proposal thresholds despite preliminary positive results.
📋 Key Facts
- The Annual Meeting was originally convened on October 14, 2025.
- Preliminary tabulation shows the Issuance Proposal, Charter Amendment Proposal, and Auditor Ratification Proposal all received sufficient votes for approval.
- The meeting is adjourned to allow more time for proxy solicitation.
- The reconvened Annual Meeting is scheduled for October 21, 2025, at 10:00 a.m. ET.
- The record date remains August 20, 2025.
OS Therapies Inc. filed a prospectus supplement related to an existing S-3 registration statement. This filing facilitates the resale of up to 4,373,043 shares of common stock by certain selling stockholders.
🚩 Red Flags
- Potential for significant dilution or downward price pressure as existing large holders liquidate positions (resale of 4.37M shares).
📋 Key Facts
- Filed a Prospectus Supplement under Form S-3 (File No. 333-289443) on September 30, 2025.
- The supplement covers the resale of up to 4,373,043 shares of common stock by selling stockholders.
- Included a legal opinion from Olshan Frome Wolosky LLP regarding the legality of the shares.
OS Therapies Inc. closed a second warrant exercise inducement offering to encourage existing warrant holders to convert their $1.12 warrants into common stock in exchange for new warrants with an exercise price of $3.00. The transaction is expected to generate approximately $3.78 million in gross proceeds to fund commercial preparations for OST-HER2.
🚩 Red Flags
- Repeated financing activity: This is the second inducement offering, following three previous reports in June and July 2025.
- Significant potential dilution: The issuance of over 3.3 million new warrant shares at a higher strike price suggests an attempt to manage capital structure amidst liquidity needs.
- Downside protection for holders: New warrants include a 'dilutive issuance' provision that protects warrant holders from future low-priced equity raises, further diluting common shareholders.
📋 Key Facts
- Closed a second warrant exercise inducement and exchange offer on September 2, 2025.
- Existing warrants (issued Dec 2024/Jan 2025) had an exercise price of $1.12 per share.
- New Warrants issued to 'Remaining Holders' have an exercise price of $3.00 per share and a 5-year term.
- The offering involves the issuance of up to 3,373,043 New Warrant Shares.
- Gross proceeds are estimated at approximately $3,777,808 before transaction fees.
- Includes a 'dilutive issuance' clause: if subsequent equity is sold below $3.00, the exercise price drops to the lower price or $1.00 (whichever is greater).
- The company will file an S-3 registration statement within 30 days to register resale of these new warrants.
OS Therapies Inc. has terminated its Equity Line of Credit (ELOC) Purchase Agreement with Square Gate Capital Master Fund, LLC — Series 3. The termination is effective as of August 26, 2025.
🚩 Red Flags
- Termination of a primary financing vehicle (ELOC) may indicate a shift in capital strategy or difficulty in accessing traditional equity markets, though no debt remains outstanding.
📋 Key Facts
- Termination of the ELOC Purchase Agreement dated October 31, 2024.
- The agreement allowed for the sale of up to $15.0 million in common stock.
- As of the termination date (August 26, 2025), there were no outstanding borrowings or shares to be issued under the agreement.
- No termination fees or payments are due from either party.
OS Therapies Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025, and provided a general business update via press release.
📋 Key Facts
- Report date: August 19, 2025
- Reporting period: Quarter ended June 30, 2025
- Company status: Clinical-stage cancer immunotherapy and ADC biotechnology company
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
OS Therapies Inc. has amended its Bylaws to reduce the quorum requirement for stockholder meetings. The amendment changes the required quorum from a standard majority (implied) to one-third of the voting power of outstanding shares present in person or by proxy.
🚩 Red Flags
- Reduction of quorum requirements can be used to facilitate corporate actions with minimal shareholder participation/engagement.
- Lowering the threshold for a quorum makes it easier for a minority of shareholders to conduct business, which may disadvantage passive or non-participating investors.
📋 Key Facts
- Amendment adopted on August 15, 2025.
- Amends Section 3.10 of Article III of the Company's Amended and Restated Bylaws.
- New quorum requirement: one-third (1/3) of the voting power of outstanding shares entitled to vote, present in person or by proxy.
- The amendment applies to both general stockholder meetings and specific class votes.
OS Therapies completed a warrant exercise inducement offering, resulting in the issuance of approximately 3.76 million new warrants at an exercise price of $3.00 per share to induce holders of existing warrants to exercise for cash.
🚩 Red Flags
- Significant potential dilution from the issuance of 3.76 million new warrants.
- Anti-dilution provisions in New Warrants allow for further downward adjustment of the exercise price if future equity is sold at a discount.
- The company is using an inducement offering, which often signals liquidity constraints or a need to accelerate cash inflows from existing debt/warrant holders.
📋 Key Facts
- Completed final closing of warrant exercise inducement and exchange offer on July 11, 2025.
- Gross proceeds from the offering are approximately $4,216,794.
- Existing warrants (exercise price $1.12) were induced to exercise for cash.
- New Warrants issued: up to an aggregate of 3,764,995 shares at an exercise price of $3.00 per share.
- New Warrants have a five-year term and are immediately exercisable.
- Includes a 'Dilutive Issuance Price' clause: if equity is sold below $3.00 (but above $1.00), the new warrant exercise price adjusts downward.
OS Therapies completed a second closing of a warrant exercise inducement offering on June 26, 2025. The company raised approximately $616,000 in gross proceeds by incentivizing existing warrant holders to exercise their warrants at $1.12 per share in exchange for new warrants with an exercise price of $3.00.
🚩 Red Flags
- Significant dilution risk due to the issuance of new warrants and subsequent resale registration.
- The 'dilutive issuance' provision allows for further downward adjustment of the warrant exercise price, potentially increasing future dilution.
- Small capital raise ($616k) relative to typical micro-cap operational needs suggests ongoing liquidity pressure.
📋 Key Facts
- Second closing of a warrant exercise inducement and exchange offer completed on June 26, 2025.
- Gross proceeds from the second closing: approximately $616,000.
- Existing warrants were exercised at an exercise price of $1.12 per share.
- New warrants issued have an exercise price of $3.00 per share and a 5-year term.
- The company is required to file a Resale Registration Statement (S-3 or S-1) for the new warrant shares within 30 days.
- Includes a 'dilutive issuance' clause: if future equity is sold at less than $3.00, the exercise price drops to the lower price (floor of $1.00).
OS Therapies entered into inducement agreements to encourage holders of existing warrants (exercise price $1.12) to exercise them for cash in exchange for new warrants with a significantly higher exercise price of $3.00. The company expects to raise approximately $8 million in gross proceeds to fund regulatory and pre-commercial efforts.
🚩 Red Flags
- Significant dilution potential from the issuance of new warrants at a higher strike price.
- Use of an inducement offer suggests difficulty in raising capital through traditional means or urgent need for liquidity.
- The 'Dilutive Issuance Price' clause allows the exercise price to drop as low as $1.00 if subsequent equity is sold at a lower price, creating further dilution risk.
📋 Key Facts
- Inducement period: June 20, 2025, to July 10, 2025.
- Existing warrants exercise price: $1.12 per share.
- New warrants exercise price: $3.00 per share (immediately exercisable, 5-year term).
- Total shares involved in inducement: up to 1,574,288 shares.
- Expected gross proceeds: approximately $8 million.
- Solicitation agent fee: 5.0% of total gross cash proceeds plus up to $15,000 in expenses.
OS Therapies Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of the release of quarterly earnings data.
📋 Key Facts
- Company announced financial results for the fiscal quarter ending March 31, 2025.
- The report was filed on May 16, 2025.
- The company is a clinical-stage cancer immunotherapy and ADC biotechnology firm.
OS Therapies Inc. completed the acquisition of HER2-based immune-oncology programs (ADXS-503 and ADXS-504) from Ayala Pharmaceuticals for an aggregate price of $8 million, primarily consisting of equity.
🚩 Red Flags
- Significant dilution: The issuance of 'Consideration Shares' and warrants represents a substantial amount of equity, including an additional 444,041 shares pending stockholder approval.
- Registration rights agreement requires the company to file registration statements for Ayala's shares within 75 days, potentially leading to future selling pressure.
📋 Key Facts
- Acquisition includes two FDA IND filings: ADXS-503 (Non-Small Cell Lung Cancer) and ADXS-504 (Prostate Cancer).
- Total purchase price is $8,000,000, comprised of $500,000 in cash/third-party payments and $7,500,000 in Company common stock.
- The deal significantly reduces future liabilities: eliminates $3.5M in milestone payments and $16.5M in sales milestones previously owed to Ayala.
- Royalty obligations for the OST-HER2 program were reduced from 10% of net sales (to Ayala) to 1.5% of net sales (to University of Pennsylvania).
- Ayala received a portion of consideration via shares and warrants due to NYSE ownership limitations.
OS Therapies Inc. held a Special Meeting of Stockholders on April 9, 2025, to seek approval for the issuance of common stock via conversion of Series A Senior Convertible Preferred Stock and exercise of various warrants. The proposal was approved by a significant majority of votes cast.
🚩 Red Flags
- Significant potential dilution: The issuance could exceed 20% of the company's common stock outstanding.
- Complex capital structure involving Series A Senior Convertible Preferred Stock and multiple warrants.
- The scale of the conversion/exercise suggests a heavy reliance on convertible instruments to fund operations.
📋 Key Facts
- Special Meeting held on April 9, 2025, at Olshan Frome Wolosky LLP in New York.
- The meeting sought approval for the issuance of shares via (i) conversion of 1,775,750 shares of Series A Senior Convertible Preferred Stock and (ii) exercise of warrants from a recent private placement.
- The Issuance Proposal involves amounts that could collectively equal or exceed 20% of common stock outstanding as of Dec 24, 2024.
- Voting results: 11,587,018 votes 'For', 74,984 votes 'Against', and 11,921 abstentions.
- Total shares voted: 11,673,923.
OS Therapies Inc. announced the adjournment of its Special Meeting of Stockholders held on March 31, 2025, due to a lack of quorum. The meeting is scheduled to reconvene on April 9, 2025, to vote on proposals previously detailed in a February 28, 2025 proxy statement.
🚩 Red Flags
- Failure to reach a quorum at a Special Meeting suggests significant shareholder apathy or disagreement regarding the proposals.
- Adjourned meetings often indicate high volatility or uncertainty surrounding the outcome of critical corporate actions (e.g., board changes, mergers, or structural reorganizations).
📋 Key Facts
- Special Meeting held on March 31, 2025, failed to reach a quorum.
- Meeting adjourned without conducting any business.
- Reconvened meeting is scheduled for April 9, 2025, at 10:00 a.m. ET in New York, NY.
- Record date remains February 12, 2025.
- The company is actively soliciting proxies to ensure a quorum and vote completion.
OS Therapies Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ended December 31, 2024. The filing serves as a formal announcement of the release of their latest earnings press release.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Quarter and year ended December 31, 2024
- Company status: Clinical-stage cancer immunotherapy and ADC biotechnology company
- Exchange: NYSE American (Ticker: OSTX)
OS Therapies Inc. entered into an agreement to acquire HER2 and Listeria monocytogenes (Lm) related intellectual property from Ayala Pharmaceuticals, Inc. for a total consideration of $8 million, consisting of $500,000 in cash and $7.5 million in common stock.
🚩 Red Flags
- Significant equity issuance ($7.5M in stock) likely to cause dilution for existing shareholders.
- The transaction involves complex warrant structures and potential NYSE ownership limitation issues (19.99% threshold).
📋 Key Facts
- Acquisition includes two FDA Investigational New Drug (IND) filings: ADXS-503 (NSCLC) and ADXS-504 (Prostate Cancer).
- Total purchase price is $8,000,000 ($500k cash / $7.5M in common stock).
- The deal significantly reduces future royalty obligations from 10% of net sales to 1.5% under the Penn License.
- Eliminates $3.5 million in milestone payments and $16.5 million in sales-based milestones previously owed to Ayala.
- Ayala will receive a warrant for shares if they exceed a 9.99% ownership threshold, subject to NYSE rules and shareholder approval.
- Seller (Ayala) is subject to a 180-day lock-up agreement on the consideration shares.
OS Therapies Inc. has completed the second closing of its private placement, bringing total gross proceeds from both closings to approximately $7.1 million. The Board of Directors has declared the Private Placement complete with no further closings scheduled.
🚩 Red Flags
- Dilution risk: The influx of $7.1M via private placement typically involves the issuance of new securities, which may dilute existing shareholders.
📋 Key Facts
- Completed the second closing of a previously announced Private Placement on January 14, 2025.
- Total aggregate gross proceeds from both the first and second closings amount to approximately $7,103,000.
- The Board of Directors has determined the Private Placement is now complete; no further closings will occur.
- Proceeds are reported before deducting transaction fees and other estimated expenses.
OS Therapies Inc. completed a second closing of its private placement on January 10, 2025, raising approximately $1.05 million through the sale of Series A Senior Convertible Preferred Stock and warrants. The filing includes amendments to existing purchase and registration rights agreements to facilitate additional closings.
🚩 Red Flags
- High liquidation preference (150%) for Series A Preferred Stock, which can dilute common shareholders in a liquidity event.
- Significant dilution potential via warrants and the 300% registration rights coverage for shares underlying the preferred stock/warrants.
- Restrictive covenants preventing additional common stock issuance except under specific equity line of credit terms (minimum 300% of conversion price).
- The company is in a continuous fundraising cycle (second closing of an ongoing placement).
📋 Key Facts
- Second closing completed on January 10, 2025.
- Sold 263,250 Units (one share of Series A Preferred Stock and one warrant per unit) for gross proceeds of ~$1,053,000.
- Units priced at $4.00 per Unit.
- Series A Preferred Stock features a liquidation preference of 150% of the original issue price.
- Mandatory conversion triggers include qualified public offerings/PIPEs >$10M/$20M at ≥$12.00/share, or stock price performance (300% of conversion price for 20 days).
- The company is an emerging growth company.
- Placement agent Brookline Capital Markets received a cash fee of $35,157 and warrants.
OS Therapies completed a private placement of Series A Senior Convertible Preferred Stock and warrants on December 31, 2024, raising approximately $6.05 million in gross proceeds. The filing also details a waiver agreement with an existing ELOC investor to prevent technical defaults caused by this new financing.
🚩 Red Flags
- Significant dilution potential: The registration rights cover 300% of the shares initially issuable under the new units.
- Complex conversion triggers: Mandatory conversion at a $12.00 price floor may create significant downward pressure or volatility near that level.
- High liquidation preference: Series A holders have a 150% liquidation preference, prioritizing them significantly over common shareholders.
- ELOC/Death Spiral characteristics: The involvement of an ELOC investor and the need for waivers to prevent defaults suggests tight liquidity management.
📋 Key Facts
- Completed private placement of 1,512,500 Units (one share of Series A Preferred Stock and one warrant per unit) at $4.00 per Unit.
- Gross proceeds from the closing totaled approximately $6,050,000 before transaction fees.
- Series A Preferred Stock includes a 150% liquidation preference.
- Mandatory conversion triggers for Series A include public offerings/PIPEs >$10M/$20M at $12.00+ per share, or the stock trading at >300% of conversion price for 20 consecutive days.
- The Company entered a Registration Rights Agreement to register 300% of the shares issuable under the new Units within 30-45 days.
- Entered into a Waiver and Agreement with ELOC Investor (Square Gate Capital Master Fund, LLC) involving cash payments and additional share issuances ($118,230.62 value).
OS Therapies Inc. entered into a Securities Purchase Agreement for a private placement of Series A Senior Convertible Preferred Stock and warrants, aiming to raise between $6 million and $10 million. The deal includes highly dilutive terms, including a mandatory conversion trigger based on stock price performance and an automatic price reset mechanism.
🚩 Red Flags
- Highly dilutive terms: The Series A Preferred Stock includes an automatic downward reset mechanism for the conversion price.
- Liquidation preference: Holders have a 150% liquidation preference, which is senior to common stock.
- Mandatory conversion triggers: Conversion can be triggered if the stock price exceeds 300% of the conversion price for 20 consecutive days or upon certain acquisition terms.
- Voting Agreement: Officers and directors are required to vote their shares in favor of this transaction, potentially limiting minority shareholder influence.
📋 Key Facts
- Private placement of Units (Series A Preferred Stock + Warrant) at $4.00 per Unit.
- Aggregate gross proceeds expected to be between $6 million and $10 million.
- Expected closing date is on or about December 31, 2024.
- Warrants have an initial exercise price of $4.40 per share.
- Series A Preferred Stock includes a liquidation preference of 150% of the original issue price.
- Automatic one-time reset of conversion/exercise prices on March 15, 2025 (or upon stockholder approval), to the lower of a 10-day VWAP or lowest closing price, with a floor of $1.00.
OS Therapies Inc. filed an 8-K to announce the release of its third quarter financial results for the period ended September 30, 2024.
📋 Key Facts
- Reporting date: November 15, 2024
- Period covered: Third Quarter ended September 30, 2024
- The filing is a standard announcement of financial results via press release (Exhibit 99.1).
OS Therapies entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC-Series 3 for a potential $15 million capital raise over the next 24 months. The agreement allows the company to sell shares at a significant discount (95% of VWAP) via 'Put Notices' at its sole discretion.
🚩 Red Flags
- Highly dilutive financing structure (Equity Purchase Agreement/Put Option).
- Significant discount to market price (5% floor on VWAP) increases dilution pressure.
- Downside protection for the investor: If stock drops below 70% of closing, the pricing formula changes to a more favorable rate for the investor.
- Potential for rapid share supply hitting the market via the Registration Rights Agreement.
📋 Key Facts
- Maximum commitment amount: $15,000,000 in common stock.
- Term: 24 months (expires October 31, 2026).
- Pricing mechanism: 95% of the lowest daily VWAP during the valuation period; or a lower price if the stock falls below 70% of its closing price on the Put Date.
- Issuance limit: Each 'Put' cannot exceed 4.99% of outstanding common stock.
- Initial consideration: Investor receives shares worth 3% of the Maximum Commitment Amount as part of the agreement.
- Registration: Company must file an S-1 registration statement by November 15, 2024.
OS Therapies Inc. announced a significant restructuring of its Board of Directors effective October 28, 2024. The Chairman and one director resigned simultaneously, while two new directors with deep pharmaceutical and regulatory expertise were appointed to fill the vacancies.
🚩 Red Flags
- Simultaneous departure of the Chairman and another director can sometimes signal internal friction, though the filing explicitly denies disagreements.
📋 Key Facts
- Chairman of the Board Colin Goddard, Ph.D., resigned effective October 28, 2024.
- Director Joacim Borg resigned effective October 28, 2024.
- Avril McKean Dieser (VP, Head of Legal Patient Evidence at UCB, Inc.) appointed to the Board.
- Olivier R. Jarry (CEO of Libera Bio S.L.) appointed to the Board.
- The company stated that neither resignation was due to a disagreement with operations, policies, or practices.
OS Therapies Inc. issued a press release to clarify its trading information for market participants and brokerage firms. The filing confirms the company's common stock trades on the NYSE American under CUSIP 68764Y207.
📋 Key Facts
- Company issued a clarification regarding its stock trading details on August 22, 2024.
- Common stock is traded on the NYSE American exchange.
- The specific CUSIP for the common stock is 68764Y207.
OS Therapies Inc. issued an 8-K to furnish its press release announcing financial results for the second quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 15, 2024
- Reporting period: Second Quarter ended June 30, 2024
- Company status: ADC and immunotherapy research and clinical-stage biopharmaceutical company
- The filing is a standard announcement of quarterly financial results via Exhibit 99.1.